PMV Pharma Cash Decreases to $112.9 Million
As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations was $73.6 million for the year ended December 31, 2025, compared to $51.3 million for the year ended December 31, 2024.
Trade with 70% Backtested Accuracy
Analyst Views on PMVP
No data
About PMVP
About the author
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Company Announcement: PMV Pharmaceuticals, Inc. will participate in investor conferences on May 27 and June 5, 2025, with live audio webcasts available for both events.
About PMV Pharma: The company focuses on developing small molecule therapies targeting p53 mutations, which are present in about half of all cancers, leveraging over four decades of research in p53 biology.
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
Clinical Trial Updates: PMV Pharmaceuticals is progressing in the Phase 2 portion of the PYNNACLE clinical trial for rezatapopt, with over 60% of sites activated and an interim analysis expected by mid-2025. The eligibility criteria for the Phase 1b combination arm have been adjusted to align with the Phase 2 patient population.
Financial Overview: As of June 30, 2024, PMV Pharma reported $212.9 million in cash and equivalents, a net loss of $1.2 million for the quarter, and increased research and development expenses due to higher contractual costs, while general administrative expenses decreased.
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024
PMV Pharmaceuticals Reports 2025 Financial Results and Future Milestones
- Deteriorating Financials: PMV Pharmaceuticals reported a net loss of $77.7 million for 2025, translating to $1.48 per share, which is a significant increase from the previous year's loss of $58.7 million, highlighting the high costs associated with clinical-stage operations and R&D investments.
- Cash Flow Outlook: As of December 31, 2025, PMV had $112.9 million in cash and equivalents, down from $183.3 million the prior year, indicating increased financial pressure with an expected runway until the second quarter of 2027.
- Clinical Trial Progress: The ongoing PYNNACLE trial is evaluating Rezatapopt's efficacy in patients with TP53 Y220C mutations, with preliminary results showing a 50% overall response rate in ovarian cancer patients, suggesting promising clinical potential.
- FDA Fast Track Designation: In March 2026, the FDA granted Fast Track designation and Orphan Drug status to Rezatapopt for treating TP53 Y220C positive ovarian cancer, indicating significant market potential, with plans to submit a New Drug Application in Q1 2027.
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial
Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.
Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Company Announcement: PMV Pharmaceuticals, Inc. will participate in investor conferences on May 27 and June 5, 2025, with live audio webcasts available for both events.
About PMV Pharma: The company focuses on developing small molecule therapies targeting p53 mutations, which are present in about half of all cancers, leveraging over four decades of research in p53 biology.
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
Clinical Trial Updates: PMV Pharmaceuticals is progressing in the Phase 2 portion of the PYNNACLE clinical trial for rezatapopt, with over 60% of sites activated and an interim analysis expected by mid-2025. The eligibility criteria for the Phase 1b combination arm have been adjusted to align with the Phase 2 patient population.
Financial Overview: As of June 30, 2024, PMV Pharma reported $212.9 million in cash and equivalents, a net loss of $1.2 million for the quarter, and increased research and development expenses due to higher contractual costs, while general administrative expenses decreased.
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024
